Barclays Initiates AbbVie (ABBV) with Overweight Rating on Growth Potential

Core Insights - AbbVie Inc. is recognized as one of the 14 Best Low Volatility Dividend Stocks to Invest in [1] - Barclays initiated coverage of AbbVie with an Overweight rating and set a price target of $275, indicating that current consensus estimates do not fully capture AbbVie's operating leverage potential [2] - Positive results from AbbVie's proof-of-concept studies could lead to stock price appreciation due to potential multiple expansion [2] Regulatory Approval - AbbVie received FDA approval for a supplemental new drug application for the combination of VENCLEXTA® (venetoclax) and acalabrutinib for adult patients with chronic lymphocytic leukemia (CLL) who have not received prior treatment [3] - This combination is the first and only all-oral, fixed-duration regimen available for previously untreated CLL patients, allowing for treatment completion and time off therapy [4] Company Overview - AbbVie is a global biopharmaceutical company focused on the research, development, and commercialization of medicines across various therapeutic areas, including immunology, oncology, aesthetics, neuroscience, and eye care [5]